[144] ABBOTT LABORATORIES SEC Filing

Rhea-AI Filing Summary

Abbott Laboratories (ABT)1,586 shares of common stock through UBS Financial Services on the NYSE, with an indicated aggregate market value of $203,042 as of the notice. The filing notes that there were 1,738,871,947 shares of common stock outstanding, providing context for the size of the planned sale.

The shares to be sold come from vested restricted stock awards. Three separate restricted stock award vestings dated 02/28/2025 are listed, for 740, 250, and 596 common shares, all acquired from the issuer, with payment dated 11/25/2025 and the nature of payment shown as “N/A.” The notice includes the standard Rule 144 representation that the seller does not know of undisclosed material adverse information about Abbott’s current or prospective operations.

11/25/2025 - 04:08 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 1000 Harbor Blvd. 3rd Floor Weehawken NJ 07086	1586	203042	1738871947	11/25/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2025	Restricted Stock Award Vested	Issuer			740	11/25/2025	N/A
Common	02/28/2025	Restricted Stock Award Vested	Issuer			250	11/25/2025	N/A
Common	02/28/2025	Restricted Stock Award Vested	Issuer			596	11/25/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Abbott Laboratories (ABT) Form 144 filing report?

The Form 144 reports a planned sale of 1,586 shares of Abbott Laboratories common stock under Rule 144, to be executed through UBS Financial Services on the NYSE.

What is the aggregate market value of the ABT shares to be sold?

The filing shows an aggregate market value of $203,042 for the 1,586 common shares of Abbott Laboratories to be sold.

How many Abbott (ABT) shares are outstanding according to this notice?

The notice states that 1,738,871,947 shares of Abbott Laboratories common stock were outstanding, giving context to the size of the planned sale.

What is the source of the Abbott (ABT) shares being sold under Rule 144?

The shares come from restricted stock awards that vested on 02/28/2025, in three tranches of 740, 250, and 596 Abbott common shares acquired from the issuer.

When is the approximate sale date for the ABT shares in this Form 144?

The Form 144 lists an approximate sale date of 11/25/2025 for the 1,586 Abbott Laboratories common shares to be sold on the NYSE.

What representation does the seller make in Abbott’s (ABT) Form 144?

The seller represents that they do not know any material adverse information about Abbott’s current or prospective operations that has not been publicly disclosed.